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Abstract
Background—In Cancer and Leukemia Group B 39801, we evaluated whether induction
chemotherapy before concurrent chemoradiotherapy would result in improved survival, and
demonstrated no significant benefit from the addition of induction chemotherapy. The primary
objective of this analysis was to dichotomize patients into prognostic groups using factors predictive
of survival, and to investigate if induction chemotherapy was beneficial in either prognostic group.
Patients and Methods—A Cox proportional hazard model was used to assess the impact on
survival of the following factors: (≥ 70 vs. < 70 years), gender, race, stage (IIIB vs. IIIA), hemoglobin
(hgb) (< 13 vs. ≥13 g/dl), performance status (PS) (1 vs.0), weight loss (≥5% vs. < 5%), treatment
arm, and the interaction between weight loss and hgb.
Results—Factors predictive of decreased survival were weight loss ≥ 5%, age ≥ 70 years, PS of 1,
and hgb < 13 g/dl (p<0.05). Patients were classified as having ≥2 poor prognostic factors (n=165) or
≤ 1 factor (n=166). The hazard ratio (HR) for overall survival for the patients with ≥ 2 versus patients
with ≤ 1 was 1.88 (95% CI, 1.49 to 2.37; p= < 0.0001); median survival times observed were 9 (95%
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CI, 8 to 11) and 18 (95% CI, 16 to 24) months, respectively. There was no significant difference in
survival between treatment arms in patients with ≥ 2 factors (HR=0.86, 95% CI, 0.63 to 1.17; p=0.34)
or ≤1 factor (HR=0.97, 95% CI, 0.70 to 1.35; p=0.87)
Conclusions—There is no evidence that induction chemotherapy is beneficial in either prognostic
group.
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Lung cancer is the leading cause of cancer-related mortality in the United States, and it is
estimated that in 2008 more patients died from lung cancer than prostate, breast, and colorectal
cancer combined.1 Eighty-seven percent of patients with lung cancer have non-small cell lung
cancer (NSCLC), and approximately one third of patients with NSCLC will have stage III
disease at the time of diagnosis.2,3 Phase III trials have demonstrated an improvement in
survival with the combination of chemotherapy and radiotherapy over radiation alone for
patients with stage III NSCLC, and for appropriate patients with a good performance status
combined modality therapy is the standard of care in the United States.4 However, there has
been significant variability in the overall survival observed on combined modality therapy
trials. The median survival time and 5-year survival rate observed on cooperative group phase
II or III trials is 15-18 months and 25%, respectively.5 Currently a variety of factors such as
single versus multilevel nodal involvement, the presence of co-morbidities, variable definitions
of resectability and physician preference contribute to the heterogeneity of patients selected
for combined modality therapy. Differences in the patient population enrolled on the clinical
trials could have contributed to the observed differences in survival, and makes assessment of
the efficacy of treatment paradigms difficult
Cancer and Leukemia Group B (CALGB) trial 39801 was designed to investigate the impact
of induction chemotherapy in addition to standard chemoradiotherapy on overall survival.6
The difference in survival was not statistically significant (p=0.3), and the median survival
observed on the induction chemotherapy followed by chemoradiotherapy and the
chemoradiotherapy arm alone arms was 14 and 12 months, respectively. The median survival
time on both treatment arms was lower than the survival observed on previous CALGB
combined modality trials.7,8 Previous CALGB trials had excluded patients with performance
status (PS) 2 and > 5% weight loss in the three months before diagnosis, but the latter criterion
was abandoned since it was felt to be redundant with PS. The lack of weight loss criteria, the
increasing acceptance of combined modality therapy, and the perception that carboplatin and
paclitaxel based chemoradiotherapy is well tolerated could have led to a broader patient
population being enrolled than on previous trials.
When eligible patients with weight loss < 5% were analyzed (n=244) the median survival was
numerically higher among patients who received chemoradiotherapy alone than among
patients who received induction chemotherapy followed by chemoradiotherapy, 16 and 14
months, respectively.6 In contrast when the eligible patients with weight loss of ≥ 5% (n=87)
were analyzed the median survival was numerically lower among patients who received
chemoradiotherapy alone than among patients who received induction chemotherapy followed
by chemoradiotherapy than chemoradiotherapy alone, 8 and 10 months, respectively.6 This
raised a question if different prognostic groups may benefit greater from one of the treatment
paradigms. In order to investigate this hypothesis we sought to identify good and poor
prognostic groups for survival and to determine if induction chemotherapy was beneficial in
either prognostic group.
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Patients were enrolled on CALGB 39801 from July 1998 to May 2002. Patients were required
to have histological or cytological documentation of NSCLC, and previously untreated
unresectable or inoperable stage III disease.9 The eligibility criteria have been published
previously,6 and the forced expiratory volume in 1 second (FEV-1) was required to be > 800
ml. Each participant signed an institutional review board (IRB) approved, protocol specific
informed consent in accordance with federal and institutional guidelines. Patient random
assignment and data collection were managed by the CALGB Statistical Center. Data quality
was ensured by careful review of data by CALGB Statistical Center staff and by the study
chairperson, following standard CALGB policies. All statistical analyses were performed by
CALGB statisticians.
As part of the quality assurance program of the CALGB, members of the Audit Committee
visit all participating institutions at least once every three years to review source documents.
The auditors verify compliance with federal regulations and protocol requirements, including
those pertaining to eligibility, treatment, adverse events, tumor response and outcome in a
sample of protocols at each institution. Such on-site review of medical records was performed
for a subgroup of 214 patients (58%) of the 366 patients under this study.
Treatment Plan
Following registration, patients were randomly assigned to one of the two treatment arms
(Figure 1). Patients on arm A received concurrent chemoradiotherapy with paclitaxel 50 mg/
m2 and carboplatin dose of area under the curve (AUC) of 2 using the Calvert equation10 weekly
for seven consecutive weeks concurrent with thoracic radiation therapy (TRT). Patients on arm
B received two cycles of induction chemotherapy with carboplatin (AUC=6) and paclitaxel
200 mg/m2 every 21 days followed by the identical concurrent chemoradiotherapy beginning
on day 43. The details of the chemotherapy administration, dose modifications, and
management of treatment related toxicity have been published previously.6
Radiation Therapy
TRT began on day 1 for patients on arm A and on day 43 for patients on arm B. Patients on
arm B who experienced extra-thoracic disease progression during induction therapy were
removed from protocol therapy, whereas patients whose disease progression was within the
planned radiation field continued their planned TRT. Concurrent radiotherapy to 66 Gy was
administered at five fractions per week for seven consecutive weeks at 2 Gy/fraction. A central
review of the radiation therapy for each case, including review of the diagnostic imaging, was
performed at the Quality Assurance Review Center (QARC) by the radiation oncology co-
chair, a thoracic radiologist, and QARC staff. The details of the radiation treatment planning
have been published previously.6
Statistical Considerations
A Cox proportional hazards model was used to assess the impact on survival of the following
factors previously reported to be prognostic among patients who received combined modality
therapy with stage III disease11-14 : age (≥70 vs. <70 years), gender (female vs. male), race/
ethnicity (non-white vs. white), hemoglobin (hgb) < 13 vs. ≥13 g/dl, PS (1 vs.0), pretreatment
weight loss (≥5% vs. <5%), stage (IIIB vs. IIIA), treatment arm, and the interaction between
weight loss and hgb. The median hgb rounded to the nearest g/dl was 13; therefore, patients
were divided into hgb of < 13 or ≥ 13 g/dl. Patients without documented weight loss (n=12)
were classified in the weight loss <5% category. Factors shown to be jointly predictive of
survival (p<0.05) were used to define two prognostic groups. The poor prognosis group was
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defined by the presence of 2 or more poor prognostic factors; whereas the good prognosis group
was defined by the presence of 1 or fewer poor prognostic factors. The Kaplan-Meier product
limit estimator was used to describe the survival experience in the two prognostic groups; a
log-rank test was conducted.
Results
The patient characteristics are summarized in Table 1. The median follow-up time for survivors
is 88 months (range 0.2 to 106 months). The Cox proportional hazards regression model
identified four factors that were significant predictors of poor survival: age ≥ 70 years, hgb <
13 g/dl, weight loss ≥ 5%, and PS of 1 (p< 0.05) (Table 2). A significant interaction effect on
overall survival between weight loss and hemoglobin was detected. The number of patients
with 0, 1, 2, or ≥ 3 poor prognostic factors and the overall survival by risk factors are
summarized in Table 3 and Figure 2. The overall survival observed for the poor prognosis
group (n=166) in comparison to good prognosis group (n=165) was significantly lower (hazard
ratio (HR) for overall survival = 1.88, 95 % CI 1.49 to 2.37; p-value <0.0001); the median
survival times observed in the poor and good prognosis groups were 9 (95% CI, 8 to 11) and
18 (95% CI, 16 to 24) months, respectively (Figure 3). The five-year overall survival rate
observed of all patients was 11.8% (95% CI, 8.7 to 15.8%), and the five-year overall survival
rate observed of the poor and good prognosis groups was 4.7% (95% CI, 2.3 to 9.4%) and
18.8% (95% CI, 13.7 to 25.9%), respectively. The reasons for discontinuation of treatment
(Table 4) and the rates of hematological toxicities and non-hematological adverse events (Table
5) were similar between the two prognostic groups. There is no significant difference between
the good and poor prognosis groups in the maximum grade of adverse event (p=0.12),
hematological adverse events (p=0.09) and non-hematological adverse events (p=0.09).
An exploratory analysis was performed to test if there was a difference in survival related to
treatment arm within the good and poor prognosis subgroups. In the poor prognosis group the
HR for overall survival for patients who received treatment on arm A (concurrent
chemoradiotherapy alone, n=82) in comparison to patients who received treatment arm B
(induction chemotherapy followed by chemoradiotherapy, n=83) was 0.86 (95% CI, 0.63 to
1.17, p=0.34); the median survival times observed on arms A and B were 8.7 (95% CI, 7.8 to
10.9) and 9.5 (95% CI, 8.2 to 14.1) months, respectively (Figure 4). In the good prognosis
group the HR for overall survival for patients on arm A (n=79) in comparison to patients on
arm B (n=87) was 0.97 (95% CI, 0.70 to 1.35; p=0.87); the median survival times observed on
arms A and B were 19.3 (95% CI, 13.2 to 25.2) and 17.6 (95% CI, 13.0 to 27.2) months,
respectively (Figure 5). In the good prognosis group the five-year overall survival rate observed
among patients on arm A and B was 19% (95% CI, 12.0 to 29.9%) and 18.6% (95% CI, 11.9
to 29.1%), respectively. In the poor prognosis group the five-year overall survival rate among
patients on arm A and B was 3.7% (85% CI, 1.2 to 11.1%) and 5.6% (95% CI, 2.3 to 13.9%),
respectively.
Discussion
Treatment with chemoradiotherapy is the standard of care for unresectable stage III NSCLC,
but the majority of patients will still experience local and/or distant disease progression and
die from progressive disease. The patient population enrolled on this trial may be more
reflective of the patient population who receive chemoradiotherapy outside the context of
clinical trial, and the treatment paradigms investigated continue to be frequently used. In order
to divide this homogenous patient population with a similar prognosis into two different
prognostic groups we divided patients based on the presence of ≥ 2 or ≤ 1 prognostic factor.
This division is arbitrary and an oversimplification of the multiple factors and complex
interactions that probably contributed to the differences in survival observed.
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In the poor prognosis group, the median survival time of 9 months observed is less than the
median survival observed with chemotherapy alone in patients with stage IIIB disease due to
pleural or pericardial effusion or metastatic disease.15-17 Median survival is arguably a sub-
optimal parameter to evaluate chemoradiotherapy treatment when the intent of the therapy is
to cure a minority of the patients. However, the long term survival of the poor prognosis patients
is also poor with a 5-year survival rate of 4.7%. This raises a concern that the majority of
patients in the poor prognosis patient population derives no long term benefit from concurrent
chemoradiotherapy and may be exposed to a therapy associated a higher rate of esophagitis
and/or myelosuppression in comparison to sequential chemotherapy and TRT or TRT alone.
18-23
The rates of hematological and non-hematologic adverse events, and maximum toxicity were
similar between the two prognostic groups (Table 4), and the percentage of patients who have
discontinued therapy related to toxicity was similar between the two prognostic groups (Table
3). These data suggest that the difference in survival between the prognostic groups did not
result from excessive toxicity or the inability to complete the protocol therapy. Another
potential confounding factor is that the patients in the poor prognosis group may have
experienced extra-thoracic disease progression at a higher rate due to the fact that constitutional
symptoms such as weight loss are frequently associated with occult metastatic disease.
However, the percentage of patients who discontinued therapy due to disease progression (4%
and 5%, respectively) and due to death (2% and 5%, respectively) was similar in the poor and
good prognostic groups. Thus, disease progression while on therapy does not appear to be
responsible for the differences in survival.
In the original analysis among eligible patients with weight loss ≥ 5% (n=87) a numerically
longer median survival was observed on arm B, and in contrast among the eligible patients
with weight loss < 5% (n=244) a numerically longer survival was observed on arm A. These
numerical differences observed in survival led us to perform an exploratory analysis of effect
of the treatment arm in the poor (n=165) and good prognosis groups (n=166). These data
provide no evidence that patients in each prognostic subgroup will benefit from induction
chemotherapy in addition to concurrent chemoradiotherapy over concurrent
chemoradiotherapy alone. Importantly, this retrospective analysis lacks statistical power to
definitively determine a lack of benefit of induction chemotherapy and should be interpreted
cautiously.
Only 66 patients enrolled on this trial (20% of the entire patient population) had no factors
predictive of poor survival. Of the remaining patients in the good prognosis group only 5%
were age ≥ 70 and 7% had weight loss ≥ 5%. Patients with an hgb < 13 g/dl (17%) or a PS of
1 (31%) were more common. The median survival time of 18 months observed in this good
prognosis patient population is similar to a previous CALGB trial for unresectable stage III
disease.7 A direct comparison of the prevalence of these adverse factors in this trial and other
trials is difficult due to the lack of reporting of all the risk factors we used and differences in
eligibility criteria.7,8,24-26
Outside the context of a clinical trial the percentage of patients who receive chemoradiotherapy
who fit the criteria for the good prognosis category may be different due to patient and physician
selection related to trial participation and the eligibility requirements of clinical trials. A recent
review of a population-based cancer registry of patients with locally advanced lung cancer
revealed that only a minority of patients would be eligible for concurrent chemoradiotherapy
trials.27 The majority of the patients had NSCLC (81%), and patients were analyzed for trial
eligibility according to the most lenient inclusion parameters from recent and ongoing
concurrent chemoradiation trials: age ≤ 74 years, PS ≤ 2, weight loss <10% in last three months,
and FEV-1 at least 40% age-predicted value. Of the 686 patients analyzed 408 patients (59%)
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were considered ineligible for trial participation. A significant percentage (23.3%) of the
patients were excluded based on age ≥ 75 years, but in the age group of 60 to 69 only 50% of
patients were eligible, and in the age group of 70 to 74 less than half were eligible. Thus, the
patients with stage III disease who participate in clinical trials may represent a select group of
patients, and the patients in the good prognosis category may represent an even more select
group of patients.
This trial was performed before positron emission tomography (PET) was routinely performed
in the staging of patients with NSCLC. Approximately 25% of patients with clinical stage III
disease will have metastatic disease detected by PET scans.28 PET scan staging has led to a
statistically significant increase in the proportion of patients being determined to have stage
IV disease, and patients who have stage III or IV disease using PET scan staging have an
improved survival compared to patients who have stage III or IV determined by conventional
staging.29 The proportion of patients with metastatic disease detected with PET scan staging
may be higher in patients with the clinical characteristics associated with the poor prognosis
group. Thus, PET scan staging may reduce the percentage of stage III patients with
characteristics of the poor prognosis group.
The use of weekly low dose carboplatin and paclitaxel with concurrent radiotherapy may have
compromised the efficacy of both treatment paradigms investigated in this trial. The trials that
have demonstrated a benefit of concurrent chemoradiotherapy over sequential chemotherapy
and radiotherapy have used systemic dose cisplatin-based therapy concurrent with the
radiotherapy.18,30 However, when newer agents (e.g. taxanes and gemcitabine) are used the
chemotherapy dose must be reduced to avoid excessive toxicity. A phase III trial that compared
weekly paclitaxel with concurrent TRT versus TRT alone after induction chemotherapy with
carboplatin and paclitaxel demonstrated a significant improvement in time to tumor
progression (p<0.001) but not overall survival in comparison to TRT alone (p=0.091).31
Carboplatin as a single agent in combination with radiation TRT appears to have limited
activity based on a previous CALGB trial,32 as well as trials by other groups.33,34
The subsequent CALGB trial, 30407, was a randomized phase II trial that investigated systemic
doses of carboplatin (AUC=5) and pemetrexed (500 mg/m2) in combination with thoracic
radiation therapy (70 Gy) with and without cetuximab. The investigational arm of carboplatin
and pemetrexed was based on the results of a promising phase I trial35, and the investigational
including cetuximab was included based on the successful results observed in the treatment of
cetuximab in combination radiation therapy in head and neck cancer.36 On preliminary
analyses the median survival time observed among patients on the carboplatin and pemetrexed
alone and with cetuximab treatment arms was 22.3 and 18.7 months, respectively.37
Other groups have retrospectively examined prognostic factors of patients who received
chemoradiotherapy for stage III disease as well. The recent Hoosier Oncology Group phase III
trial comparing cisplatin and etoposide with concurrent TRT with and without docetaxel
revealed a median survival time of 21.7 months for all patients (n=203), and no significant
difference in survival between treatment arms was observed.38 Patients with weight loss of >
5% were excluded from this trial. An analysis of the prognostic factors including age (< 70
versus ≥ 70 years) sex, race/ethnicity, body mass index, PS (0 versus 1), FEV-1 (>2 liters (L)
versus 1-2 L), smoking status (current versus never/former), hgb, stage (IIIA versus IIIB) and
the use of PET scan staging.14 A total of 203 patients were enrolled, and 26% were age ≥ 70
years, 42% had a PS of 1, and 14% had a baseline hgb < 12. On Cox regression analysis baseline
hgb level as a continuous covariate (HR=0.84; 95% CI, 0.73 to 0.96, p-value=0.012) and FEV-1
> 2 L (HR=0.57; 95% CI, 0.35 to 0.92, p-value= 0.021) were independent prognostic factors
for survival. Unfortunately we do not have baseline FEV-1 values to investigate FEV-1 as a
prognostic factor for patients treated on CALGB 39801. The previously performed Cox
Stinchcombe et al. Page 6













proportional hazards regression model for survival perform for patients who received treatment
on CALGB 39801 investigate anemia, defined as hgb < 12 g/dl, and did not find anemia
predictive of survival.6
A retrospective analysis of prognostic factors of patients who were treated on Radiation
Therapy Oncology Group (RTOG) trials 980139 and 941019 was recently performed (n=824).
13 The eligibility criteria were inoperable stage II or unresectable stage III NSCLC, a Karnofsky
Performance Status (KPS) ≥ 70, and weight loss ≤ 5%. The median baseline hgb was 13.4 g/
dl and 17% had hgb < 12 g/dl, 75% of patients had a KPS of 90-100, and 18% were age ≥ 70
years. In Cox proportional univariate hazard models KPS (90-100 vs. 70-80); nodal status (0
and 1 vs. 2 and 3), female gender, and lobar location were statistically significant. Age, stage,
gender, nodal status, KPS, tumor location and hgb were dichotomized into two levels and
patients were grouped into three cohorts of combined prognostic factors (0 or 1 vs. 2 or 3 vs.
>3). The HR for survival observed for the patient cohort of 2 or 3 and > 3 poor prognostic
factors in comparison to the cohort of 0 or 1 poor prognostic risk factors was 1.31 (95% CI,
0.99 to 1.79; p-value 0.0585) and 1.74 (95% CI, 1.28 to 2.35; p=0.0003), respectively. The
median survival observed in the three groups was 22.7, 17.3, and 13.5 months, respectively;
and the 5-year survival rates observed were 18.5, 14.7, and 9.8%, respectively.
Gross tumor volume (GTV) has been identified as a prognostic factor in patients with NSCLC
who receive radiation therapy,40-44 and the post-chemotherapy GTV after induction therapy
for patients with stage III disease may be a prognostic factor.45 Several studies have found a
poor correlation between stage and tumor volume probably due to the fact that there can be
significant variability of the tumor volume within a stage.46-48 The percentage of the total lung
volume receiving ≥ 20 Gy (V20) is a risk factor for the development of radiation pneumonitis,
and has been identified on multivariate analysis to be an independent predictor of survival.49
We did not investigate GTV or V20 as prognostic factors in this trial.
In summary, our analysis indicated that four clinical variables (age, baseline hgb, the presence
of weight loss, and performance status) were predictive of survival and if patients are divided
into prognostic subgroups there is no evidence that induction chemotherapy is beneficial in
either prognostic group.
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Figure 1. CALGB 390801: Study Design
Abbreviations: AUC = Area Under the Curve; TRT = Thoracic Radiation Therapy
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Figure 2. CALGB 39801: Overall Survival by Risk Factors (n=331)
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Figure 3. CALGB 39801: Overall survival by Good Prognosis vs. Poor Prognosis (n=331)
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Figure 4. CALGB 39801: Overall survival by treatment arm in the poor prognosis group (n=165)
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Figure 5. CALGB 39801: Overall Survival by treatment arm in the good prognosis group (n=166)
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Median Age, years (Range) 63 (37-85) 68 (37-85) 60(38-81)
 <70 247 (75) 89 (54) 158 (95)
 ≥70 84 (25) 76 (46) 8 (5)
Gender
 Male 218 (66) 105 (64) 113 (68)
 Female 113 (34) 60 (36) 53 (32)
Ethnicity
 White 282 (85) 132 (80) 150 (90)
 African American 40 (12) 27 (16) 13 (8)
 Hispanic American 5 (2) 3 (2) 2 (1)
 Other 4 (2) 3 (2) 1 (1)
Performance Status
 0 148 (45) 34 (21) 114 (69)
 1 183 (55) 131(79) 52 (31)
Weight loss
 <5%* 244 (74) 90 (55) 154 (93)
 ≥5% 87 (26) 75 (45) 12 (7)
Stage
 IIIA 168 (51) 77 (47) 91 (55)
 IIIB 163 (49) 88 (53) 75 (45)
Hemoglobin
 ≥13g/d1 181 (55) 43 (26) 138 (83)
 <13g/d1 150 (45) 122 (74) 28 (17)
Treatment arms
Arm A 161 (49) 82 (50) 79 (48)
Arm B 170 (51) 83 (50) 87 (52)
*
The 12 patients with no documentation of weight loss were included in the <5% weight loss category; 7 patients were treated on arm A and 5 patients
were treated on arm B
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Table 2
Cox Proportional Hazard Model
Variable Hazard Ratio 95% CI P-value
Weight loss (≥5% vs <5%) 1.92 1.33 to 2.76 <0.01
Hgb (<13 vs ≥ 13) 1.65 1.24 to 2.20 <0.01
Age (≥70 vs <70) 1.45 1.11 to 1.90 0.01
PS (1 vs 0) 1.35 1.06 to 1.71 0.01
Race (Non-White vs White) 1.28 0.91 to 1.79 0.15
Stage (IIIB vs IIIA) 1.11 0.87 to 1.40 0.40
Arm (Arm A vs Arm B) 0.94 0.75 to 1.18 0.60
Gender (Female vs Male) 0.89 0.70 to 1.14 0.34
Weight loss * Hgb 0.49 0.29 to 0.81 0.01
Abbreviations: CI=confidence interval, hgb=hemoglobin, PS=performance status, arm A=concurrent chemoradiotherapy, arm B=induction chemotherapy
and concurrent chemoradiotherapy Weight loss
*
hgb: the interaction between weight loss and hemoglobin
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Table 3
Median Survival by Risk factors
Number of factors Number of patients Median survival (95% CI)
0 66 24 months (14 to 25)
1 100 18 months (13 to 22)
2 100 10 months (9 to 14)
≥ 3 65 8 months (7 to 10)
Abbreviations: CI=confidence interval
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Table 4





Treatment Completed 119 (72) 118 (71)
Adverse Events 17 (10) 25 (15)
Disease Progression 9 (5) 7 (4)
Died 9 (5) 4 (2)
Patient Refusal 4 (2) 3 (2)
Taken off protocol treatment 2 (1) 2 (1)
Other 3 (2) 3 (2)
Missing 2 (1) 4 (2)
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Table 5
Select Adverse events in the Good and Poor Prognosis groups
Variable Poor Prognosis (n=165) Good Prognosis (n=166)
Grade 3 (%) Grade 4 (%) Grade 3 (%) Grade 4 (%)
Hematologic
Febrile Neutropenia 4 (3) 1 (1) 4 (2) 1 (1)
Hemoglobin 11 (7) 0 (0) 15 (9) 0 (0)
Neutropenia 39 (24) 25 (15) 21 (13) 25 (15)
Red blood cell transfusion 9 (5) 0 (0) 9 (5) 0 (0)
Thrombocytopenia 3 (2) 0 (0) 10 (6) 0 (0)
Maximum toxicity 80 (48) 40 (24) 83 (50) 33 (20)
Non Hematologic
Anorexia 19 (12) 8 (5) 21 (13) 9 (5)
Dysphagia-esophageal 39 (24) 6 (4) 48 (29) 7 (4)
Dyspnea 20 (12) 8 (5) 18 (11) 3 (2)
Fatigue 21 (13) 6 (4) 30 (18) 1 (1)
Nausea 10 (6) 0 (0) 14 (8) 0 (0)
Pneumonitis 7 (4) 4 (2) 7 (4) 1 (1)
Vomiting 8 (5) 0 (0) 10 (6) 0 (0)
Weight loss 8 (5) 0 (0) 4 (2) 0 (0)
Maximum toxicity 78 (47) 26 (16) 82 (50) 26 (16)
*
There were 3 grade 5 non-hematological adverse events; 2 (1%) in the poor prognosis group and 1 (1%) in the good prognosis group
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